CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

Fabio Guolo, Luana Fianchi, Paola Minetto, Marino Clavio, Michele Gottardi, Sara Galimberti, Giuliana Rizzuto, Michela Rondoni, Giambattista Bertani, Michela Dargenio, Atto Bilio, Barbara Scappini, Patrizia Zappasodi, Anna Maria Scattolin, Francesco Grimaldi, Giuseppe Pietrantuono, Pellegrino Musto, Marco Cerrano, Stefano D'Ardia, Ernesta AudisioAlessandro Cignetti, Crescenza Pasciolla, Francesca Pavesi, Anna Candoni, Carmela Gurreri, Monica Morselli, Caterina Alati, Nicola Fracchiolla, Giovanni Rossi, Manuela Caizzi, Fabrizio Carnevale-Schianca, Agostino Tafuri, Giuseppe Rossi, Felicetto Ferrara, Livio Pagano, Roberto Massimo Lemoli

Research output: Contribution to journalArticlepeer-review

Abstract

Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71 (8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was observed in 10/50 patients (20%) and 12 months cumulative incidence of relapse (CIR) was 23.6%. Median duration of response was not reached. In competing risk analysis, CIR was reduced when HSCT was performed in first CR (12 months CIR of 5% and 37.4%, respectively, for patients receiving (=20) or not (=30) HSCT, p = 0.012). Twelve-months OS was 68.6% (median not reached). In landmark analysis, HSCT in CR1 was the only significant predictor of longer survival (12 months OS of 100 and 70.5%, for patients undergoing or not HSCT in CR1, respectively, p = 0.011). In conclusion, we extend to a real-life setting, the notion that CPX is an effective regimen for high risk AML patients and may improve the results of HSCT.

Original languageEnglish
Article number96
JournalBlood Cancer J.
Volume10
Issue number10
DOIs
Publication statusPublished - Oct 6 2020

Fingerprint

Dive into the research topics of 'CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.'. Together they form a unique fingerprint.

Cite this